Welcome to our dedicated page for Nu Skin Enter news (Ticker: NUS), a resource for investors and traders seeking the latest updates and insights on Nu Skin Enter stock.
Nu Skin Enterprises, Inc. reports developments tied to its beauty and wellness business, affiliate opportunity platform and international market operations. Company updates commonly cover quarterly revenue and earnings, customer, paid affiliate and sales leader trends, dividend declarations, cost discipline and product commercialization across Nu Skin personal care, Pharmanex nutrition and ageLOC anti-aging brands.
Recurring news also includes the rollout of Prysm iO, an intelligent wellness platform that uses skin scans to provide antioxidant-related insights, and activity at Rhyz, the company’s strategic investment arm for consumer, technology and manufacturing businesses in beauty, wellness and lifestyle categories. Leadership appointments and operating-structure changes are also part of the company’s public updates.
Summary not available.
Summary not available.
Nu Skin Enterprises (NYSE: NUS) announced the resignation of CFO Mark Lawrence, effective March 31, 2023, to pursue other opportunities. Lawrence will continue as a senior advisor until April 2023 to ensure a smooth transition. The board has appointed James D. Thomas, previously the chief accounting officer, as interim CFO while searching for a permanent replacement. The company reaffirmed its first-quarter and annual guidance for 2023, initially provided on February 15, 2023. Nu Skin will release its Q1 results on May 3, 2023, followed by a conference call with investors.
Nu Skin Enterprises, Inc. (NYSE: NUS) reported Q4 2022 revenue of $522.3 million, down 22% year-over-year, impacted by foreign exchange (FX) losses of $51 million. EPS for the quarter was $1.15, improving from a loss of $(0.18) in Q4 2021. For FY 2022, revenue totaled $2.23 billion, down 17%. Looking ahead, Q1 2023 revenue is projected between $450 to $490 million, a decline of 26% to 19%. Annual revenue guidance for 2023 ranges from $2.03 billion to $2.18 billion. The company anticipates ongoing macroeconomic challenges but remains optimistic about its long-term strategy and growth prospects.
Nu Skin Enterprises (NYSE: NUS) announced a quarterly cash dividend increase to $0.39 per share, payable on March 8, 2023, to shareholders recorded by February 27, 2023. This increase marks the 22nd consecutive year of dividend growth, showcasing the company's commitment to returning value to shareholders. Chief Financial Officer Mark Lawrence emphasized the company's strong financial position and its confidence in its long-term direction.
Nu Skin Enterprises, Inc. (NYSE: NUS) announced it has provided 800 million meals to malnourished children globally through its Nourish the Children initiative since 2002. The initiative enables purchases of VitaMeal, a nutrient-rich food, which is then donated to those in need via third-party charities. The success of this program, highlighted by the company’s executive chairman Steven J. Lund, reflects its significant social impact. Nu Skin continues its commitment to address childhood hunger while promoting its health and wellness products.
Nu Skin Enterprises, Inc. (NYSE: NUS) will announce its fourth quarter and full year 2022 financial results on February 15, 2023, after market closure. A conference call with management for investors will follow at 5 p.m. ET on the same day, discussing recent results and future business initiatives. The recorded webcast of this call will be accessible through the company's investor relations page until March 1, 2023.
Nu Skin Enterprises (NYSE: NUS) announced its involvement in the 76th Annual Scientific Meeting of the Society of Cosmetic Chemists in Los Angeles on December 12, 2022. The event is a key gathering for cosmetic science, featuring over 1,000 attendees. Nu Skin scientists are presenting research on a proprietary blend of green tea and alpha-tocopherol for cellulite visibility, while Vice President Dr. Helen Knaggs moderates a panel on beauty trends. Additionally, Paul Cox, Ph.D., will present a keynote on ethnobotanical drug candidates for neurodegenerative diseases.
Nu Skin Enterprises, Inc. (NYSE: NUS) has announced that its ageLOC® LumiSpa® iO has won the 2022 "New Product of the Year" award from the Business Intelligence Group. This beauty and cleansing device, recognized for its innovative micropulse oscillation technology, connects to the Nu Skin Vera app to enhance personalized skincare experiences. The LumiSpa iO has contributed to Nu Skin's status as the leading brand in beauty device systems for five consecutive years. The awards highlight innovations aiming to transform consumer experiences.
Nu Skin Enterprises (NYSE: NUS) unveiled the ageLOC® LumiSpa® iO, a smart skin treatment and cleansing device, on November 17, 2022, in Provo, Utah. This device features patented micropulse technology, offering personalized skincare options, intelligent coaching, and routine tracking through the Nu Skin Vera app. Users can create customized facial treatments and track their progress, with clinical studies noting user improvements in skin softness (58%), smoothness (47%), brightness (40%), and radiance (34%). The device is designed for daily use and is available now in the U.S.